Global Interstitial Cystitis Market – Industry Trends and Forecast to 2030

Global Interstitial Cystitis Market, By Severity (Mild To Moderate, Moderate To Severe), Treatment Type (Medication, Bladder Instillations, Botulinum Toxin A, Nerve Stimulation, Surgery), Route of Administration (Oral, Parenteral, Intravesical, Topical, Others), Mode of Purchase (Over The Counter, Prescription), Patient Type (Paediatric, Adults), End User (Hospitals, Clinics, Home Healthcare, Others), Distribution Channel (Direct Tender, Retail Sales, Others) - Industry Trends and Forecast to 2030.

Interstitial Cystitis Market Analysis and Size

The growth and development of interstitial cystitis can be influenced by a multitude of factors, making it a complex and challenging condition to understand. Several key elements contribute to the expansion and persistence of IC. As per December 2020, World Health Organization (WHO) report stated that global healthcare expenditure was rising in 2018, which was USD 8.3 trillion, which is around 10% of GDP (USD1.080 per citizen) compared to USD 7.6 trillion in 2016. Moreover, global health spending grew by 3.9 percent between 2000 and 2017.

Data Bridge Market Research analyses that the interstitial cystitis market which was USD 1,246.55 million in 2022, would rocket up to USD 1,991.84 million by 2030, and is expected to undergo a CAGR of 10.5% during the forecast period 2023 to 2030. “Moderate to severe” of the severity segment is expected to dominate the market due to the rising prevalence of interstitial cystitis and other gastro related disorders. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation

Market Definition

A persistent illness known as interstitial cystitis causes bladder pressure, bladder pain and pelvic pain. Mild discomfort to severe agony is all possible levels of pain. The disorder belongs to a group of illnesses called painful bladder syndrome. Different tests are performed by doctors to diagnose the painful bladder disorder, which include X-rays, urine tests and a bladder wall examination using a cystoscope. It is characterized by pain, pressure, or discomfort perceived to be related to the urinary bladder that lasts more than six months with at least one other urinary symptom, such as frequency or persistent urge. These bladder disorders cause inflammation in the bladder, which is generally called cystitis. Treatment of the disorder depends on the cause of the problem. It may include medication and surgery in severe cases.

Global Interstitial Cystitis Market Dynamics

Drivers

• Rising Prevalence of Interstitial Cystitis

The disorder known as interstitial cystitis (IC), also known as bladder discomfort syndrome, is chronic or long-lasting and it produces uncomfortable urine symptoms. Individuals with IC may experience varied symptoms. For example, some persons experience little pressure, pain, or discomfort in the pelvic region. Others may battle with severe bladder pain, urinary urgency—the sudden need to urinate—or frequency—the desire to urinate more frequently. One of the main factors influencing the growth rate of the interstitial cystitis market is the increasing prevalence of interstitial cystitis nowadays. Women are particularly affected by this condition. Common side effects include allergies, fibromyalgia and endometriosis. Urinary frequency, urgency and pelvic pain are clinical symptoms of interstitial cystitis, which can occur both during the day and at night.

• Growing Geriatric Population

The global aging population is more prone to IC, as the condition is more common in women and tends to occur in middle age. The demographic shift toward an older population is expected to boost the demand for IC-related products and treatments.

Opportunities

• Rising Technological Advancements

Improvements in diagnostic techniques, including cystoscopy, hydrodistention, and biomarker discovery, have enhanced the early detection and diagnosis of IC. This facilitates timely intervention and treatment. Advancements in medical technology and minimally invasive procedures have expanded the range of treatment options available to IC patients, including neuromodulation and intravesical therapy.

• Increasing Healthcare Expenditure

The cost of healthcare has climbed globally as people's disposable income has increased in different countries. In addition, government agencies and healthcare providers are taking the initiative by increasing healthcare spending in order to meet population needs. Growing healthcare expenditure is also benefiting further economic growth and healthcare sector growth. It is primarily helpful as it significantly affects the development of better and advanced medical products in the market. Thereby surge in healthcare expenditure is expected to act as a driver for the global interstitial cystitis market.

Restraints/ Challenges

• Strict Regulations and Guidelines

Regulations in the market play a significant role in ensuring the safety, efficacy, and availability of treatments and medical devices for IC patients. In most countries, pharmaceutical treatments for IC must undergo regulatory approval before they can be marketed and sold to the public. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA) in the United States, the European Medicines Agency (EMA) in the European Union, and similar agencies in other regions, review clinical trial data and evidence to assess the safety and efficacy of IC medications.

• High Cost Associated with Technology

The high cost of treatment is a significant challenge in the global interstitial cystitis (IC) market. Diagnosis of IC often involves various diagnostic tests and procedures, such as cystoscopy and urodynamic studies. These tests can be expensive and may require multiple visits to healthcare facilities. Patients may need to cover a portion of the costs, including co-pays, deductibles, and co-insurance, which can be significant for those with high-deductible insurance plans.

• Limited reimbursement scenario

The reimbursement scenario for treatments related to interstitial cystitis (IC) varies from one country to another and is influenced by the healthcare system, government policies, and the availability of approved treatments. Insurance providers may have different policies regarding IC treatments. Some treatments, such as oral medications, may be covered with lower copayments, while more invasive or experimental treatments may have limited coverage or require pre-authorization. It is common for patients to face challenges in getting certain treatments approved by insurers.

This interstitial cystitis market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the interstitial cystitis market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In July 2020, UCB and Ferring Pharmaceuticals Inc. announced they had entered into a co-promotion agreement to commercialize the prefilled syringe formulation of CIMZIA used for interstitial cystitis

Global Interstitial Cystitis Market Scope

The global interstitial cystitis market is segmented into severity, treatment type, route of administration, mode of purchase, patient type, end user, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.

Severity

• Mild To Moderate
• Moderate To Severe

Treatment Type

• Medications
• Bladder Instillation
• Botulinum Toxin A
• Nerve Stimulation
• Surgery

Route of Administration

• Oral
• Parenteral
• Intravesical
• Topical
• Others

Mode of Purchase

• Over the counter
• Prescription

Patient Type

• Pediatric
• Adults

End User

• Hospitals
• Clinics
• Home Healthcare
• Others

Distribution Channel

• Direct tender
• Retail sales
• Others

Global Interstitial Cystitis Market Regional Analysis/Insights

The interstitial cystitis market is analysed and market size insights and trends are provided by country, severity, and treatment type, route of administration, and mode of purchase, patient type, end user, and distribution channel, as referenced above.

The interstitial cystitis market comprises of the countries U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Turkey, Russia, Netherlands, Switzerland, Belgium and Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, and rest of the Middle East and Africa.

North America is dominating the market. The increasing investment in R&D over the past few years is expected to boost the market growth. Also, the growing geriatric population in the region with more prone to the disease is expected to boost the growth of the market  

Asia-Pacific is the fastest growing region due to the rising need for the verification and validation of interstitial cystitis treatment processes in the region and rapid research development is boosting the market

The country section of the report also provides individual market-impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, disease epidemiology and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of global brands and their challenges faced due to high competition from local and domestic brands and the impact of sales channels are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

The Interstitial Cystitis market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for Interstitial Cystitis market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the Interstitial Cystitis market. The data is available for historic period 2011-2021.

Competitive Landscape and Global Interstitial Cystitis Market Share Analysis

The interstitial cystitis market competitive landscape provides details by the competitors. Details include company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth and application dominance. The above data points are only related to the companies focus on the market.   

Some of the major players operating in the interstitial cystitis market are:

• Alvogen (U.S.)
• Janssen Pharmaceuticals, Inc. (U.S.)
• Sandoz AG (Switzerland)
• Sun Pharmaceutical Industries Ltd. (India)
• Accord Healthcare (U.S.)
• Avet Pharmaceuticals Inc. (U.S.)
• Lannett (U.S.)
• Viatris Inc. (U.S.)
• Pfizer, Inc. (U.S.)
• Strides Pharma Science Limited (India)
• GSK plc. (U.K.)
• Prestige Consumer Healthcare Inc. (U.S.)
• Amneal Pharmaceuticals LLC (U.S.)
• Zydus Pharmaceuticals, Inc. (India)
• Apotex Inc. (Canada)
• Aurobindo Pharma (India)
• VistaPharm, Inc. (U.S.)
• Dr. Reddy’s Laboratories, Inc. (U.S.)
• Teva Pharmaceuticals, Inc. (Israel)
• Bayer AG (Germany)
• Reckitt Benckiser Group PLC (U.K.)